每日低剂量他达拉非可改善膀胱疼痛综合征/间质性膀胱炎患者的疼痛和频率。

IF 1 Q4 UROLOGY & NEPHROLOGY
Pedro Abreu Mendes, Nuno Dias, Jose Simaes, Paulo Dinis, Francisco Cruz, Rui Pinto
{"title":"每日低剂量他达拉非可改善膀胱疼痛综合征/间质性膀胱炎患者的疼痛和频率。","authors":"Pedro Abreu Mendes,&nbsp;Nuno Dias,&nbsp;Jose Simaes,&nbsp;Paulo Dinis,&nbsp;Francisco Cruz,&nbsp;Rui Pinto","doi":"10.5152/tud.2022.21292","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients.</p><p><strong>Material and methods: </strong>A total of 14 refractory BPS/IC female patients, previously evaluated with a physical examination, bladder diary, bladder-pain related visual analogue score, O'Leary-Sant Scores (OSS) for symptoms and problems, and quality of life (QoL) question from International Prostate Symptom Score, were treated with 5mg of tadalafil, for 3months. Re-evaluations occurred at 4 and 12weeks. Adverse events were assessed and recorded.</p><p><strong>Results: </strong>Urinary frequency, OSS, and QoL were significantly improved at 1-month follow-up (10 6 2.5, 21.9 6 4.1, and 4 6 1.5, respectively, P < .05). Pain intensity and volume voided were significantly improved at a 3-month follow-up (3.5 6 2 and 266.7 6 60.5, P < .05). Patients referred to urinary frequency as the most important parameter improved at 4weeks, and pain at 3months. No differences between ulcerated and nonulceratedpatients were observed. Two patients dropped out due to unsatisfactory results and two due to persistent headache and/or tachycardia, but both events were resolved after discontinuing the drug.</p><p><strong>Conclusion: </strong>Daily low-dose tadalafil is an easy, well-tolerated, and effective treatment for refractory BPS/IC in women.</p>","PeriodicalId":23366,"journal":{"name":"Turkish journal of urology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3e/tju-48-1-82.PMC9612742.pdf","citationCount":"1","resultStr":"{\"title\":\"Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients.\",\"authors\":\"Pedro Abreu Mendes,&nbsp;Nuno Dias,&nbsp;Jose Simaes,&nbsp;Paulo Dinis,&nbsp;Francisco Cruz,&nbsp;Rui Pinto\",\"doi\":\"10.5152/tud.2022.21292\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients.</p><p><strong>Material and methods: </strong>A total of 14 refractory BPS/IC female patients, previously evaluated with a physical examination, bladder diary, bladder-pain related visual analogue score, O'Leary-Sant Scores (OSS) for symptoms and problems, and quality of life (QoL) question from International Prostate Symptom Score, were treated with 5mg of tadalafil, for 3months. Re-evaluations occurred at 4 and 12weeks. Adverse events were assessed and recorded.</p><p><strong>Results: </strong>Urinary frequency, OSS, and QoL were significantly improved at 1-month follow-up (10 6 2.5, 21.9 6 4.1, and 4 6 1.5, respectively, P < .05). Pain intensity and volume voided were significantly improved at a 3-month follow-up (3.5 6 2 and 266.7 6 60.5, P < .05). Patients referred to urinary frequency as the most important parameter improved at 4weeks, and pain at 3months. No differences between ulcerated and nonulceratedpatients were observed. Two patients dropped out due to unsatisfactory results and two due to persistent headache and/or tachycardia, but both events were resolved after discontinuing the drug.</p><p><strong>Conclusion: </strong>Daily low-dose tadalafil is an easy, well-tolerated, and effective treatment for refractory BPS/IC in women.</p>\",\"PeriodicalId\":23366,\"journal\":{\"name\":\"Turkish journal of urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3e/tju-48-1-82.PMC9612742.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish journal of urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/tud.2022.21292\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish journal of urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/tud.2022.21292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:膀胱疼痛综合征/间质性膀胱炎(BPS/IC)是一种慢性疾病,发病率高。越来越多的证据表明,膀胱传入高兴奋性,通过神经源性膀胱炎症和尿路上皮功能障碍,在BPS/IC的病理生理中起关键作用。使用磷酸二酯酶5型抑制剂(PDE5i)的基本原理是减少膀胱传入亢进。尿逼肌松弛、微循环改善和肾上腺素能伤害性过度活动的减少可能是膀胱组织的其他影响。我们的目的是评估每日低剂量5mg他达拉非治疗难治性BPS/IC患者的疗效、耐受性和安全性。材料和方法:共14例难治性BPS/IC女性患者,先前通过体格检查、膀胱日记、膀胱疼痛相关视觉模拟评分、症状和问题的O'Leary-Sant评分(OSS)以及国际前列腺症状评分中的生活质量(QoL)问题进行评估,给予5mg他他非治疗3个月。在第4周和第12周进行重新评估。评估并记录不良事件。结果:随访1个月,两组患者尿频、OSS、QoL均有显著改善(分别为10.6 2.5、21.9 6.6 4.1、4.6 1.5,P < 0.05)。随访3个月,疼痛强度和排尿量明显改善(分别为3.5 6 2和266.7 6 60.5,P < 0.05)。患者将尿频作为最重要的参数,在第4周改善,疼痛在第3个月改善。溃疡和非溃疡患者之间没有差异。2名患者因治疗结果不理想而退出,2名患者因持续头痛和/或心动过速而退出,但这两种事件在停药后都得到了解决。结论:每日小剂量他达拉非是治疗难治性BPS/IC的一种简便、耐受性良好、有效的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients.

Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients.

Objective: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients.

Material and methods: A total of 14 refractory BPS/IC female patients, previously evaluated with a physical examination, bladder diary, bladder-pain related visual analogue score, O'Leary-Sant Scores (OSS) for symptoms and problems, and quality of life (QoL) question from International Prostate Symptom Score, were treated with 5mg of tadalafil, for 3months. Re-evaluations occurred at 4 and 12weeks. Adverse events were assessed and recorded.

Results: Urinary frequency, OSS, and QoL were significantly improved at 1-month follow-up (10 6 2.5, 21.9 6 4.1, and 4 6 1.5, respectively, P < .05). Pain intensity and volume voided were significantly improved at a 3-month follow-up (3.5 6 2 and 266.7 6 60.5, P < .05). Patients referred to urinary frequency as the most important parameter improved at 4weeks, and pain at 3months. No differences between ulcerated and nonulceratedpatients were observed. Two patients dropped out due to unsatisfactory results and two due to persistent headache and/or tachycardia, but both events were resolved after discontinuing the drug.

Conclusion: Daily low-dose tadalafil is an easy, well-tolerated, and effective treatment for refractory BPS/IC in women.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Turkish journal of urology
Turkish journal of urology Medicine-Urology
CiteScore
2.10
自引率
0.00%
发文量
53
期刊介绍: The aim of the Turkish Journal of Urology is to contribute to the literature by publishing scientifically high-quality research articles as well as reviews, editorials, letters to the editor and case reports. The journal’s target audience includes, urology specialists, medical specialty fellows and other specialists and practitioners who are interested in the field of urology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信